“It'll start to -- the numbers will be more meaningful in FY '27 for us, the actual revenue, the lagging indicators. And again, it will be -- it's very profitable right out of the gate for us.”

In context

“oing way better than any of those models. And so now we just got to build this market. It's all those things we said, Danielle. But again, where we're really excited where you feel the energy is it all starts with those patient outcomes and how this is resonating with consumers. So the other thing we're going to do over time besides building the referral pathway, working with hospitals is building the brand around Simplicity, right? So all of the 50,000 to 2.5 million I talked about of site visits, that's all about lead development, lead generation. We'd also like to build the brand of Simplicity and make it synonymous with hypertension management. So that's going to be an investment that Thierry talked about for FY '27. So a lot of exciting -- a lot of excitement right now in Ardian. And It'll start to -- the numbers will be more meaningful in FY '27 for us, the actual revenue, the lagging indicators. And again, it will be -- it's very profitable right out of the gate for us. Ingrid Goldberg: And as we reach the top of the hour here, our last question is going to come from Joanne Wuensch from Citi. And before we move to Joanne, please, of course, e-mail us for any of those we did not reach today. Sorry, and thank you, and we'll look forward to talking to you soon. Joanne Wuensch: I'm going to ask the Stealth AXiS question and what you can share with us about the product and why you're so excited about it? Geoffrey Martha: Well, thanks, Joanne, for that question. I -- first of all, like I said, I do think this is -- has been -- is meaningfully underappreciated in the not so much maybe in the clinical community from spine surgeons, but maybe in the investment community because, look, this robot does 2 things. First of all, it's not an extension of Mazor. It's a”